BackNeogenomics Overview
Neogenomics Inc.

Neogenomics Target Price

See Neogenomics's analyst price targets ($19) vs the current share price.

Get informed when a big investor buys or sells

+ Follow

Share Price

$17.38

Average Target Price

$19.009.3% upside

1 analysts in the last 4 months

High: $19 | Low: $19

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-07-29Craig-Hallum$199.3% upsideOpen
2026-04-29Leerink Partners$2543.8% upsideOpen
2026-02-24Piper Sandler$1325.2% downsideOpen
2025-10-28Leerink Partners$1419.4% downsideOpen
2025-09-02Stephens$1136.7% downsideOpen
2025-08-04Piper Sandler$1136.7% downsideOpen
2025-07-30Morgan Stanley$854% downsideOpen
2025-07-29Needham$854% downsideOpen
2025-05-06Piper SandlerDavid Westenberg$1231% downsideOpen
2025-01-11BTIGMark Massaro$183.6% upsideOpen
2024-07-30NeedhamMike Matson$199.3% upsideOpen
2024-05-02BTIGMark Massaro$2120.8% upsideOpen
2023-08-21StephensMason Carrico$183.6% upsideOpen
2022-08-17Piper SandlerDavid Westenberg$199.3% upsideOpen
2022-08-10Morgan Stanley$183.6% upsideOpen
2022-08-10Goldman Sachs$2015.1% upsideOpen
2022-08-10Needham$167.9% downsideOpen
2022-04-28Raymond James$1513.7% downsideOpen
2021-06-03Goldman SachsMatthew Sykes$55216.5% upsideOpen
2021-05-25GuggenheimSandy Draper$54210.7% upsideOpen

Neogenomics (NEO) FAQ

Neogenomics posts a target price of $19. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

A target price of $19 for NEO means covering analysts, on average, see the stock 9.3% upside of $17.38 over about 12 months. Dig into who set the high and low targets and how recently they updated — freshness matters as much as the average itself.

Context for NEO's target price usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Neogenomics's other metric pages and overview cover the third.

Judging Neogenomics against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in target price easier to interpret. Start with $19 here, then scan peer and history charts to see if the gap is persistent.